Research Article
Prognostic Factors in Dedifferentiated Chondrosarcoma: A Retrospective Analysis of a Large Series Treated at a Single Institution
Table 1
The clinicopathological characteristics and treatment modalities in patients with dedifferentiated chondrosarcoma.
| | | Total | Nonmetastatic | Metastatic |
| | Characteristics | 72 | 49 (68.1%) | 23 (31.9%) |
| | Age | | | | | ≤60 years | 34 (47.2%) | 25 (51.0%) | 9 (39.1%) | | >60 years | 38 (52.8%) | 24 (49.0%) | 14 (60.9%) |
| | Gender | | | | | Female | 27 (37.5%) | 18 (36.7%) | 9 (39.1%) | | Male | 45 (62.5%) | 31 (63.3%) | 14 (60.9%) |
| | Pathological fracture | 28 (38.9%) | 16 (32.7%) | 12 (52.2%) |
| | Site | | | | | Extremity | 47 (65.3%) | 30 (61.2%) | 17 (73.9%) | | Trunk | 25 (34.7%) | 19 (38.8%) | 6 (26.1%) |
| | Tumor size | | | | | ≤8 cm | 20 (27.8%) | 14 (28.6%) | 6 (26.1%) | | >8 cm | 48 (66.7%) | 31 (63.3%) | 17 (73.9%) | | Discontinuous | 4 (5.6%) | 4 (8.2%) | 0 (0.0%) |
| | Lymph node involvement | 3 (4.2%) | 0 (0.0%) | 3 (13.0%) |
| | Grade | | | | | G2 | 18 (25.0%) | 12 (24.5%) | 6 (26.1%) | | G3 | 54 (75.0%) | 37 (75.5%) | 17 (73.9%) |
| | AJCC 7th edition stage | | | | | II | 45 (62.5%) | 45 (91.8%) | 0 (0.0%) | | III | 4 (5.6%) | 4 (8.2%) | 0 (0.0%) | | IV | 23 (31.9%) | 0 (0.0%) | 23 (100.0%) |
| | Extra-osseous extension | 69 (95.8%) | 46 (93.9%) | 23 (100.0%) |
| | Lymphovascular invasion | | | | | No | 46 (63.9%) | 35 (71.4%) | 11 (47.8%) | | Yes | 9 (12.5%) | 5 (10.2%) | 4 (17.4%) | | NA | 17 (23.6%) | 9 (18.4%) | 8 (34.8%) |
| | Dedifferentiated component | | | | | Osteosarcoma | 26 (36.1%) | 20 (40.8%) | 6 (26.1%) | | UPS | 26 (36.1%) | 20 (40.8%) | 6 (26.1%) | | Fibro/myofibroblastic sarcoma | 11 (15.3%) | 8 (16.3%) | 3 (13.0%) | | Undifferentiated spindle cell sarcoma | 10 (13.9%) | 5 (10.2%) | 5 (21.7%) | | Rhabdomyosarcoma | 2 (2.8%) | 1 (2.0%) | 1 (4.3%) | | Angiosarcoma | 1 (1.4%) | 1 (2.0%) | 0 (0.0%) |
| | Size of dedifferentiated component | | | | | Microscopic | 11 (15.3%) | 8 (16.3%) | 3 (13.0%) | | Macroscopic | 61 (84.7%) | 41 (83.7%) | 20 (87.0%) |
| | Chemotherapy | 25 (34.7%) | 14 (28.6%) | 11 (47.8%) |
| | Local treatment | | | | | Surgery | 47 (65.3%) | 32 (65.3%) | 15 (65.2%) | | Radiation | 4 (5.6%) | 1 (2.0%) | 3 (13.0%) | | Radiation > surgery | 6 (8.3%) | 6 (12.2%) | 0 (0.0%) | | Radiation > surgery > radiation | 5 (6.9%) | 4 (8.2%) | 1 (4.3%) | | Surgery > radiation | 8 (11.1%) | 6 (12.2%) | 2 (8.7%) | | No surgery or radiation | 2 (2.8%) | 0 (0.0%) | 2 (8.7%) |
| | Surgical margin | | | | | R0 | 53 (73.6%) | 39 (79.6%) | 14 (60.9%) | | R1 | 2 (2.8%) | 2 (4.1%) | 0 (0.0%) | | R2 | 11 (15.3%) | 7 (14.3%) | 4 (17.4%) | | No surgery | 6 (8.3%) | 1 (2.0%) | 5 (21.7%) |
|
|
AJCC, American Joint Committee on Cancer, 7th edition; NA, not available; UPS, undifferentiated pleomorphic sarcoma.
|
